MedPath

Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome

Conditions
Myelodysplastic Syndrome
Registration Number
NCT02330692
Lead Sponsor
Yonsei University
Brief Summary

Developing a molecular genetic test that can identify prognostic factors which can predict response to treatment, and to contribute to the establishment of future therapeutic strategies base on prognostic factors by undergoing peripheral blood and bone marrow examination of Myelodysplastic Syndrome (MDS) patients at diagnosis and relapse.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
1000
Inclusion Criteria
  • MDS diagnosed by bone marrow aspiration and biopsy at Severance Hospital.

    • Male and Female over 16 years of age. ③ Written consent of the patient to participate in the cohort ④ Deaths during the study period are waiver of consent
Read More
Exclusion Criteria

① Refusal or trouble understanding the written consent

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
the number of patients with MDS to examine new prognostic factors10 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Severance Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath